Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Testicular Neoplasms | 6 | 2023 | 800 | 2.540 |
Why?
|
Radiation Oncology | 6 | 2024 | 563 | 2.410 |
Why?
|
Neoplasms, Second Primary | 5 | 2023 | 1051 | 2.170 |
Why?
|
Prostatic Neoplasms | 23 | 2024 | 11106 | 1.910 |
Why?
|
Radiosurgery | 5 | 2024 | 1339 | 1.690 |
Why?
|
Seminoma | 2 | 2023 | 134 | 1.630 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 7 | 2023 | 1655 | 1.240 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2024 | 2223 | 1.200 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 491 | 1.010 |
Why?
|
Salvage Therapy | 5 | 2024 | 1263 | 0.930 |
Why?
|
Radiotherapy Dosage | 9 | 2023 | 2897 | 0.830 |
Why?
|
Penile Neoplasms | 1 | 2024 | 161 | 0.830 |
Why?
|
Oropharyngeal Neoplasms | 2 | 2018 | 491 | 0.810 |
Why?
|
Neoplasms | 10 | 2024 | 22131 | 0.790 |
Why?
|
Photons | 3 | 2021 | 589 | 0.780 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2023 | 1784 | 0.770 |
Why?
|
Prostate-Specific Antigen | 7 | 2024 | 2465 | 0.750 |
Why?
|
Nerve Sheath Neoplasms | 2 | 2012 | 170 | 0.740 |
Why?
|
Radiation Injuries | 2 | 2019 | 1189 | 0.700 |
Why?
|
Physicians, Women | 2 | 2024 | 509 | 0.690 |
Why?
|
Radiation Tolerance | 2 | 2019 | 478 | 0.690 |
Why?
|
Faculty, Medical | 3 | 2024 | 1204 | 0.670 |
Why?
|
Brachytherapy | 2 | 2017 | 1223 | 0.670 |
Why?
|
Radiobiology | 1 | 2019 | 90 | 0.640 |
Why?
|
Congresses as Topic | 1 | 2024 | 802 | 0.640 |
Why?
|
Schools, Medical | 2 | 2022 | 878 | 0.630 |
Why?
|
Minority Groups | 3 | 2023 | 1202 | 0.620 |
Why?
|
Lung Neoplasms | 7 | 2021 | 13382 | 0.580 |
Why?
|
Ablation Techniques | 1 | 2020 | 246 | 0.570 |
Why?
|
Rectal Neoplasms | 3 | 2021 | 1156 | 0.550 |
Why?
|
Prostatectomy | 5 | 2024 | 1824 | 0.550 |
Why?
|
Vaginal Neoplasms | 1 | 2017 | 104 | 0.550 |
Why?
|
Urinary Bladder | 1 | 2023 | 1151 | 0.540 |
Why?
|
Pelvis | 1 | 2020 | 732 | 0.510 |
Why?
|
Male | 53 | 2024 | 360358 | 0.500 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2020 | 474 | 0.500 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2019 | 801 | 0.490 |
Why?
|
Humans | 85 | 2024 | 760617 | 0.490 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 423 | 0.480 |
Why?
|
Societies, Medical | 2 | 2024 | 3900 | 0.480 |
Why?
|
Social Class | 1 | 2023 | 1992 | 0.470 |
Why?
|
Esophagus | 2 | 2021 | 1031 | 0.460 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2018 | 617 | 0.450 |
Why?
|
Esophagogastric Junction | 1 | 2016 | 347 | 0.440 |
Why?
|
Antidiuretic Agents | 1 | 2013 | 21 | 0.440 |
Why?
|
Diabetes Insipidus, Nephrogenic | 1 | 2013 | 20 | 0.440 |
Why?
|
Neoplasm Staging | 8 | 2023 | 11116 | 0.440 |
Why?
|
Radiology, Interventional | 1 | 2017 | 476 | 0.430 |
Why?
|
Fanconi Syndrome | 1 | 2013 | 34 | 0.430 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2013 | 87 | 0.430 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4910 | 0.420 |
Why?
|
Medulloblastoma | 1 | 2018 | 677 | 0.420 |
Why?
|
Ifosfamide | 1 | 2013 | 232 | 0.420 |
Why?
|
Nephrectomy | 1 | 2018 | 937 | 0.410 |
Why?
|
Rhabdomyoma | 1 | 2012 | 56 | 0.410 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2015 | 290 | 0.400 |
Why?
|
Urology | 1 | 2017 | 400 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2024 | 9277 | 0.390 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2016 | 549 | 0.390 |
Why?
|
Poverty | 1 | 2023 | 2692 | 0.390 |
Why?
|
Colonic Neoplasms | 2 | 2021 | 2533 | 0.380 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 341 | 0.380 |
Why?
|
Orchiectomy | 2 | 2023 | 463 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4020 | 0.380 |
Why?
|
Neoplasm Invasiveness | 3 | 2024 | 3593 | 0.370 |
Why?
|
Preimplantation Diagnosis | 1 | 2012 | 143 | 0.350 |
Why?
|
Medical Oncology | 4 | 2023 | 2317 | 0.350 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5319 | 0.350 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1378 | 0.340 |
Why?
|
Herpesvirus 4, Human | 1 | 2015 | 1077 | 0.330 |
Why?
|
Blastocyst | 1 | 2012 | 432 | 0.330 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2012 | 323 | 0.320 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2827 | 0.320 |
Why?
|
Radiation Dosage | 1 | 2017 | 1956 | 0.320 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 612 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6474 | 0.310 |
Why?
|
United States | 13 | 2024 | 72272 | 0.300 |
Why?
|
Cultural Diversity | 2 | 2022 | 369 | 0.300 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1365 | 0.300 |
Why?
|
Prostate | 7 | 2024 | 1773 | 0.290 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 560 | 0.290 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26049 | 0.290 |
Why?
|
Carcinoma, Papillary | 1 | 2012 | 785 | 0.290 |
Why?
|
Glioma | 2 | 2019 | 3453 | 0.280 |
Why?
|
Fetal Hemoglobin | 3 | 2015 | 345 | 0.280 |
Why?
|
Female | 29 | 2024 | 392148 | 0.270 |
Why?
|
Quality of Life | 4 | 2024 | 13347 | 0.270 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 3164 | 0.270 |
Why?
|
Treatment Outcome | 12 | 2023 | 64568 | 0.260 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5491 | 0.260 |
Why?
|
Thyroid Gland | 1 | 2012 | 1170 | 0.260 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7995 | 0.250 |
Why?
|
Esophageal Neoplasms | 1 | 2016 | 1653 | 0.250 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1453 | 0.250 |
Why?
|
Thyroid Nodule | 1 | 2012 | 764 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5304 | 0.240 |
Why?
|
Kidney Neoplasms | 1 | 2021 | 4250 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 2020 | 0.240 |
Why?
|
Fertilization in Vitro | 1 | 2012 | 1292 | 0.230 |
Why?
|
Physicians | 1 | 2022 | 4583 | 0.230 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20556 | 0.230 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5430 | 0.230 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 106 | 0.220 |
Why?
|
Middle Aged | 18 | 2024 | 220584 | 0.220 |
Why?
|
Aged | 16 | 2024 | 169042 | 0.220 |
Why?
|
Pediatrics | 1 | 2018 | 3588 | 0.210 |
Why?
|
Mortality | 2 | 2024 | 2899 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 36402 | 0.210 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58894 | 0.210 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 107 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.210 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2821 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.210 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 8516 | 0.200 |
Why?
|
Adult | 17 | 2024 | 220969 | 0.190 |
Why?
|
Mutation | 4 | 2024 | 30016 | 0.190 |
Why?
|
Young Adult | 8 | 2024 | 59179 | 0.180 |
Why?
|
Brain Neoplasms | 2 | 2019 | 9026 | 0.180 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3196 | 0.170 |
Why?
|
Retrospective Studies | 12 | 2024 | 80566 | 0.170 |
Why?
|
Policy | 1 | 2023 | 506 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11736 | 0.170 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2332 | 0.160 |
Why?
|
Socioeconomic Factors | 2 | 2023 | 7798 | 0.160 |
Why?
|
Cystectomy | 1 | 2023 | 634 | 0.160 |
Why?
|
Personnel Selection | 1 | 2020 | 196 | 0.160 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6807 | 0.150 |
Why?
|
Canada | 1 | 2024 | 2118 | 0.150 |
Why?
|
Evidence-Based Practice | 1 | 2022 | 494 | 0.150 |
Why?
|
Organs at Risk | 1 | 2020 | 359 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 3514 | 0.150 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6483 | 0.150 |
Why?
|
Tumor Burden | 2 | 2023 | 1892 | 0.150 |
Why?
|
Demography | 1 | 2022 | 1643 | 0.150 |
Why?
|
Cisplatin | 1 | 2023 | 1650 | 0.140 |
Why?
|
Prognosis | 5 | 2024 | 29600 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12447 | 0.140 |
Why?
|
Rectum | 1 | 2021 | 891 | 0.140 |
Why?
|
Bleomycin | 1 | 2017 | 494 | 0.130 |
Why?
|
Incidence | 3 | 2024 | 21337 | 0.130 |
Why?
|
Protons | 1 | 2021 | 1112 | 0.130 |
Why?
|
Vinblastine | 1 | 2017 | 488 | 0.130 |
Why?
|
Hemoglobinopathies | 2 | 2013 | 99 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2509 | 0.130 |
Why?
|
Survival Rate | 3 | 2019 | 12719 | 0.130 |
Why?
|
Erythroid Cells | 2 | 2015 | 238 | 0.130 |
Why?
|
Fatigue | 1 | 2022 | 1550 | 0.130 |
Why?
|
Genomics | 4 | 2024 | 5822 | 0.120 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2017 | 880 | 0.120 |
Why?
|
Prospective Studies | 5 | 2023 | 54360 | 0.120 |
Why?
|
Risk | 2 | 2020 | 9604 | 0.120 |
Why?
|
Income | 1 | 2023 | 1870 | 0.120 |
Why?
|
Dacarbazine | 1 | 2017 | 559 | 0.120 |
Why?
|
Cost Savings | 1 | 2019 | 912 | 0.110 |
Why?
|
Polyuria | 1 | 2013 | 37 | 0.110 |
Why?
|
Data Collection | 1 | 2022 | 3315 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2022 | 1409 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 491 | 0.110 |
Why?
|
Consensus | 4 | 2024 | 3117 | 0.110 |
Why?
|
Single Embryo Transfer | 1 | 2012 | 29 | 0.100 |
Why?
|
Leadership | 1 | 2022 | 1385 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1846 | 0.100 |
Why?
|
Weight Gain | 1 | 2022 | 2350 | 0.100 |
Why?
|
Intussusception | 1 | 2013 | 115 | 0.100 |
Why?
|
Adolescent | 6 | 2019 | 88234 | 0.100 |
Why?
|
Administration, Intranasal | 1 | 2013 | 476 | 0.090 |
Why?
|
Papillomaviridae | 1 | 2017 | 1117 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1745 | 0.090 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1985 | 0.090 |
Why?
|
Doxorubicin | 1 | 2017 | 2224 | 0.090 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3868 | 0.090 |
Why?
|
Retinal Detachment | 1 | 2014 | 428 | 0.090 |
Why?
|
Propensity Score | 1 | 2017 | 1911 | 0.080 |
Why?
|
Pregnancy Rate | 1 | 2012 | 648 | 0.080 |
Why?
|
Radiotherapy | 1 | 2016 | 1497 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2925 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2017 | 2008 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2917 | 0.080 |
Why?
|
Gene Silencing | 1 | 2015 | 1503 | 0.080 |
Why?
|
Biomedical Research | 1 | 2024 | 3426 | 0.080 |
Why?
|
Embryo Transfer | 1 | 2012 | 522 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4237 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39063 | 0.070 |
Why?
|
Medical Records | 1 | 2012 | 1407 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 908 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3680 | 0.070 |
Why?
|
Enhancer Elements, Genetic | 1 | 2013 | 1360 | 0.070 |
Why?
|
RNA Interference | 1 | 2015 | 2830 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15251 | 0.070 |
Why?
|
Transcriptional Activation | 1 | 2012 | 1755 | 0.070 |
Why?
|
Cell Lineage | 1 | 2015 | 2554 | 0.070 |
Why?
|
Mass Screening | 1 | 2022 | 5424 | 0.070 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 3419 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2017 | 1611 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5332 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11069 | 0.060 |
Why?
|
Registries | 1 | 2021 | 8207 | 0.060 |
Why?
|
Databases, Factual | 2 | 2018 | 7960 | 0.060 |
Why?
|
Child | 4 | 2019 | 80079 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 39913 | 0.060 |
Why?
|
Visual Acuity | 1 | 2014 | 2672 | 0.060 |
Why?
|
Parents | 1 | 2018 | 3563 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4058 | 0.060 |
Why?
|
Cause of Death | 1 | 2014 | 3683 | 0.060 |
Why?
|
Carrier Proteins | 2 | 2015 | 4935 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8645 | 0.060 |
Why?
|
Retina | 1 | 2014 | 2655 | 0.060 |
Why?
|
Carcinoma | 1 | 2015 | 2327 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2018 | 2894 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9417 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13635 | 0.050 |
Why?
|
Informatics | 1 | 2023 | 71 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9461 | 0.050 |
Why?
|
Cohort Studies | 2 | 2023 | 41457 | 0.050 |
Why?
|
Nuclear Proteins | 2 | 2015 | 5789 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2022 | 195 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10073 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 426 | 0.050 |
Why?
|
Disease Progression | 2 | 2018 | 13495 | 0.050 |
Why?
|
Sarcoma | 1 | 2012 | 1800 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 127 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2812 | 0.050 |
Why?
|
Internship and Residency | 1 | 2020 | 5878 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 23972 | 0.040 |
Why?
|
Ultrasonography | 1 | 2012 | 5964 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3805 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12043 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7389 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 384 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1088 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 846 | 0.040 |
Why?
|
Child, Preschool | 2 | 2018 | 42188 | 0.040 |
Why?
|
Hydrogels | 1 | 2023 | 720 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12966 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2022 | 1738 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11874 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 8998 | 0.030 |
Why?
|
Gene Order | 1 | 2015 | 169 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2012 | 11514 | 0.030 |
Why?
|
gamma-Globins | 1 | 2015 | 105 | 0.030 |
Why?
|
Androgens | 1 | 2022 | 1285 | 0.030 |
Why?
|
DNA Repair | 1 | 2023 | 2043 | 0.030 |
Why?
|
DNA Damage | 1 | 2023 | 2446 | 0.030 |
Why?
|
Repressor Proteins | 2 | 2015 | 2985 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2013 | 99 | 0.030 |
Why?
|
Retroviridae | 1 | 2015 | 851 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 901 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6762 | 0.020 |
Why?
|
Nucleic Acid Conformation | 1 | 2015 | 901 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6961 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2013 | 852 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1608 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2013 | 15612 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 29868 | 0.020 |
Why?
|
Gene Targeting | 1 | 2013 | 837 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 3879 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4007 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2574 | 0.020 |
Why?
|
Genetic Engineering | 1 | 2013 | 931 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 20988 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3351 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2015 | 3392 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2013 | 4611 | 0.020 |
Why?
|
Base Sequence | 1 | 2015 | 12421 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 5780 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7568 | 0.010 |
Why?
|
Chromatin | 1 | 2013 | 2955 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15576 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8833 | 0.010 |
Why?
|
Genetic Variation | 1 | 2013 | 6561 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 18937 | 0.010 |
Why?
|
Mice | 2 | 2015 | 81368 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16967 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12661 | 0.010 |
Why?
|
Transcription Factors | 1 | 2013 | 12116 | 0.010 |
Why?
|
Animals | 2 | 2015 | 168201 | 0.010 |
Why?
|
Infant | 1 | 2013 | 36152 | 0.010 |
Why?
|
Risk Factors | 1 | 2013 | 74115 | 0.000 |
Why?
|